The role of adiponectin in placentation and preeclampsia

Preeclampsia is not fully understood; and few biomarkers, therapeutic targets, and therapeutic agents for its management have been identified. Original investigative findings suggest that abnormal placentation triggers preeclampsia and leads to hypertension, proteinuria, endothelial dysfunction, and...

Full description

Saved in:
Bibliographic Details
Published in:Cell biochemistry and function Vol. 38; no. 1; pp. 106 - 117
Main Authors: Adu‐Gyamfi, Enoch Appiah, Fondjo, Linda Ahenkorah, Owiredu, William K.B.A., Czika, Armin, Nelson, William, Lamptey, Jones, Wang, Ying‐Xiong, Ding, Yu‐Bin
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01.01.2020
Subjects:
Adiponectin
Adiponectin - deficiency
Adiponectin - metabolism
Angiogenesis
biomarker
Biomarkers
Body weight
Chemical compounds
Cytokines
Decidua
Female
Humans
Hypertension
Metabolism
Metabolism, Inborn Errors - metabolism
Overweight
Pharmacology
placenta
Placentation
Pre-eclampsia
Pre-Eclampsia - metabolism
Preeclampsia
Pregnancy
Proteinuria
Signs and symptoms
Therapeutic applications
trophoblast
adiponectin
placenta
preeclampsia
biomarker
trophoblast
pregnancy
ISSN:0263-6484, 1099-0844, 1099-0844
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preeclampsia is not fully understood; and few biomarkers, therapeutic targets, and therapeutic agents for its management have been identified. Original investigative findings suggest that abnormal placentation triggers preeclampsia and leads to hypertension, proteinuria, endothelial dysfunction, and inflammation, which are characteristics of the disease. Because of the regulatory roles that it plays in several metabolic processes, adiponectin has become a cytokine of interest in metabolic medicine. In this review, we have discussed the role of adiponectin in trophoblast proliferation, trophoblast differentiation, trophoblast invasion of the decidua, and decidual angiogenesis, which are the major phases of placentation. Also, we have highlighted the physiological profile of adiponectin in the course of normal pregnancy. Moreover, we have discussed the involvement of adiponectin in hypertension, endothelial dysfunction, inflammation, and proteinuria. Furthermore, we have summarized the reported relationship between the maternal serum adiponectin level and preeclampsia. The available evidence indicates that adiponectin level physiologically falls as pregnancy advances, regulates placentation, and exhibits protective effects against the symptoms of preeclampsia and that while hyperadiponectinemia is evident in normal‐weight preeclamptic women, hypoadiponectinemia is evident in overweight and obese preeclamptic women. Therefore, the clinical use of adiponectin as a biomarker, therapeutic target, or therapeutic agent against the disease looks promising and should be considered.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0263-6484
1099-0844
1099-0844
DOI:10.1002/cbf.3458